How is stage data completeness typically evaluated across registry datasets?

How is stage data completeness typically evaluated across registry datasets?

• A. By auditing the data entry speed for stage fields.
• B. By comparing stage distributions across hospitals.
• C. By requiring a stage value for every case regardless of data quality.
• D. By calculating the percentage of cases with complete stage data (TNM and/or stage group) and monitoring trends; often part of DQIs.

Answer: (D)

Evaluating stage data completeness by calculating the percentage of cases that have known stage information (using either TNM values or a stage group) and tracking how this changes over time is the most informative approach. In cancer registries, stage can be captured in different forms—detailed TNM components or an overall stage grouping—and completeness means that a record has at least one of these representations filled in. By computing the proportion of cases with complete stage data, you get a clear, comparable metric of data coverage across the dataset or across institutions. Monitoring this metric over time as part of data quality indicators helps detect when data collection practices are slipping or when there are delays in staging information becoming available, prompting targeted quality improvement efforts. This directly measures how complete the staging information is, which is essential for valid analyses of stage-specific incidence and survival. Other options don’t measure completeness in a direct, actionable way: auditing data entry speed says nothing about whether data are present; comparing stage distributions across hospitals can reflect real differences or biases rather than completeness; and forcing every case to have a stage value regardless of data quality could mask missing data rather than measure it.

Evaluating stage data completeness by calculating the percentage of cases that have known stage information (using either TNM values or a stage group) and tracking how this changes over time is the most informative approach. In cancer registries, stage can be captured in different forms—detailed TNM components or an overall stage grouping—and completeness means that a record has at least one of these representations filled in. By computing the proportion of cases with complete stage data, you get a clear, comparable metric of data coverage across the dataset or across institutions. Monitoring this metric over time as part of data quality indicators helps detect when data collection practices are slipping or when there are delays in staging information becoming available, prompting targeted quality improvement efforts. This directly measures how complete the staging information is, which is essential for valid analyses of stage-specific incidence and survival. Other options don’t measure completeness in a direct, actionable way: auditing data entry speed says nothing about whether data are present; comparing stage distributions across hospitals can reflect real differences or biases rather than completeness; and forcing every case to have a stage value regardless of data quality could mask missing data rather than measure it.